Secukinumab 生物类似药, 人 IL17A 单克隆抗体-Secukinumab Biosimilar, Human IL17A Monoclonal Antibody代理/参数/厂家-二抗-开云·官方站线上登录平台入口

欢迎您访问武汉开云·官方站线上登录平台入口_开云(中国) 官方网站！

站点地图服务热线：400-6800-868

PRODUCT CENTER

二抗

开云·官方站线上登录平台入口_开云(中国)

当前位置：开云·官方站线上登录平台入口 > 开云·官方站线上登录平台入口_开云(中国) > 免疫学产品 > 二抗

背景资料: What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.

保存建议: Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

其他: ProMab 生物技术公司通过整合生物信息学、分子生物学、蛋白质表达、纯化技术、基因克隆、微生物学和免疫学，利用新型高通量技术开发重组蛋白、抗体和工程细胞系并将其商业化。专注于免疫治疗领域，特别是 CAR-T/NK 细胞技术。ProMab 还开发了一种新型的 mRNA 脂质纳米颗粒（mRNA-LNP）平台，用于即用型试剂和定制研究服务，以推进现有产品并扩展到更多的研究领域。